Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZYN57939 (MTR-106) 是用于治疗 RNA 聚合酶 I 介导的疾病的 RNA 聚合酶 I 抑制剂。 ZYN57939 对人 HT-29 癌细胞系显示出抑制活性,IC50 为 0.855 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,230 | 现货 | ||
5 mg | ¥ 2,510 | 现货 | ||
10 mg | ¥ 3,590 | 现货 | ||
25 mg | ¥ 5,750 | 现货 | ||
50 mg | ¥ 7,830 | 现货 | ||
100 mg | ¥ 10,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,770 | 现货 |
产品描述 | ZYN57939 (MTR-106) is RNA polymerase I inhibitor for treating RNA polymerase I- mediated diseases. ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT- 29 cancer cell lines. |
体外活性 | MTR-106, stabilizes DNA G-quadruplexes in vitro.?MTR-106 displayed significant antiproliferative activity in homologous recombination repair (HR)-deficient and PARP inhibitor (PARPi)-resistant cancer cells.?Moreover, MTR-106 increased DNA damage and promoted cell cycle arrest and apoptosis to inhibit cell growth. |
体内活性 | MTR-106 oral and i.v. administration significantly impaired tumor growth in BRCA-deficient xenograft mouse models.?However, MTR-106 showed modest activity against talazoparib-resistant xenograft models.?In rats, the drug rapidly distributes to tissues within 5 min, and its average concentrations were 12-fold higher in the tissues than in the plasma.?Overall, MTR-106 as a novel G-quadruplex stabilizer with high tissue distribution, and it may serve as a potential anticancer agent. |
别名 | MTR-106 |
分子量 | 525.62 |
分子式 | C28H27N7O2S |
CAS No. | 1639357-93-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.25 mg/ml (10 mM), Sonication is recommended.
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9025 mL | 9.5126 mL | 19.0252 mL | 47.5629 mL |
5 mM | 0.3805 mL | 1.9025 mL | 3.805 mL | 9.5126 mL | |
10 mM | 0.1903 mL | 0.9513 mL | 1.9025 mL | 4.7563 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ZYN57939 1639357-93-9 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis ZYN 57939 MTR-106 MTR 106 MTR106 ZYN-57939 Inhibitor inhibitor inhibit